亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會(huì)員第1年

山東華禧藥業(yè)有限公司  

沒有填寫主營業(yè)務(wù)~~

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:劉小姐
  • 電話:0531-61365156
  • QQ:377876712
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 供應(yīng)硫酸氫氯吡格雷
供應(yīng)硫酸氫氯吡格雷
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 山東濟(jì)南市付款后3天內(nèi)
品牌 huaxi
型號(hào) 135046-48-9
規(guī)格 類白色結(jié)晶性粉末
過期 長(zhǎng)期有效
更新 2013-01-17 14:33
 
詳細(xì)信息

品名:硫酸氫氯吡格雷Clopidogrel hydrogen sulphate

CASNO135046-48-9

化學(xué)名稱:S(+)-2-(2-氯苯基)-2-(4,5,6,7-四氫噻吩[3,2-c]并吡啶-5)乙酸甲酯硫酸氫鹽
化學(xué)結(jié)構(gòu)式:

分子式:C16H16ClNO2S•H2SO4   
分子量:419.91

外觀:白色或類白色粉末

含量:≥99.0%

用途:抗血栓醫(yī)藥原料

©2025 山東華禧藥業(yè)有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:5484  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |